FibroGen, Inc. (FGEN)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
FGEN Insider Trading Activity
FGEN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $181,587 | 4 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Schoeneck James A | director | 2 | $105,040 | 0 | $0 | $105,040 |
| Wettig Thane | CEO | 1 | $50,663 | 0 | $0 | $50,663 |
| Adib Deyaa | Chief Medical Officer | 1 | $25,884 | 0 | $0 | $25,884 |
About FibroGen, Inc.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Activity of FibroGen, Inc.
Over the last 12 months, insiders at FibroGen, Inc. have bought $181,587 and sold $0 worth of FibroGen, Inc. stock.
On average, over the past 5 years, insiders at FibroGen, Inc. have bought $325,420 and sold $2.31M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Schoeneck James A (director) — $105,040. Wettig Thane (CEO) — $50,663. Adib Deyaa (Chief Medical Officer) — $25,884.
The last purchase of 145,000 shares for transaction amount of $50,663 was made by Wettig Thane (CEO) on 2025‑03‑24.
List of Insider Buy and Sell Transactions, FibroGen, Inc.
| 2025-03-24 | Wettig Thane | CEO | 145,000 0.1361% | $0.35 | $50,663 | -7.15% | ||
| 2025-03-21 | Schoeneck James A | director | 50,000 0.0536% | $0.34 | $17,040 | +12.95% | ||
| 2025-03-20 | Schoeneck James A | director | 250,000 0.2595% | $0.35 | $88,000 | +2.24% | ||
| 2024-06-12 | Adib Deyaa | Chief Medical Officer | 22,123 0.023% | $1.17 | $25,884 | -64.64% | ||
| 2024-03-07 | Wettig Thane | CEO | 50,000 0.0545% | $1.91 | $95,470 | -71.62% | ||
| 2023-09-01 | Sale | Henderson Jeffrey William | director | 2,000 0.002% | $1.03 | $2,060 | -8.40% | |
| 2023-08-04 | Sale | Henderson Jeffrey William | director | 2,000 0.002% | $1.91 | $3,820 | -44.24% | |
| 2023-07-11 | Sale | Henderson Jeffrey William | director | 2,000 0.0021% | $2.69 | $5,380 | -58.61% | |
| 2023-07-07 | Sale | Conterno Enrique A | Chief Executive Officer | 1,880 0.0021% | $2.80 | $5,264 | -58.15% | |
| 2023-06-23 | Sale | Wettig Thane | Chief Commercial Officer | 791 0.0009% | $16.53 | $13,075 | -92.77% | |
| 2023-06-14 | Sale | Chung Christine | SVP, China Operations | 6,250 0.0068% | $16.79 | $104,925 | -92.83% | |
| 2023-06-13 | Sale | Chung Christine | SVP, China Operations | 6,250 0.0066% | $17.60 | $110,000 | -93.28% | |
| 2023-06-09 | Sale | EDWARDS JEFFREY L | director | 7,889 0.0084% | $17.19 | $135,622 | -92.99% | |
| 2023-06-09 | Sale | Blaug Suzanne | director | 8,520 0.0091% | $17.20 | $146,571 | -92.99% | |
| 2023-06-09 | Sale | Cravatt Benjamin | director | 3,944 0.0042% | $17.17 | $67,717 | -92.99% | |
| 2023-06-09 | Sale | Brennan Aoife | director | 4,733 0.0051% | $17.19 | $81,367 | -92.99% | |
| 2023-06-08 | Sale | Henderson Jeffrey William | director | 7,000 0.0073% | $17.45 | $122,185 | -93.31% | |
| 2023-06-08 | Sale | Ho Maykin | director | 8,520 0.0088% | $17.44 | $148,591 | -93.31% | |
| 2023-06-07 | Sale | Conterno Enrique A | Chief Executive Officer | 8,897 0.0093% | $17.04 | $151,583 | -93.02% | |
| 2023-06-07 | Sale | Chung Christine | SVP, China Operations | 3,633 0.0038% | $17.04 | $61,894 | -93.02% |
Insider Historical Profitability
| Wettig Thane | CEO | 543329 0.5384% | $186,144.52 | 3 | 7 | <0.0001% |
| Schoeneck James A | director | 373722 0.3703% | $128,037.16 | 2 | 8 | |
| Adib Deyaa | Chief Medical Officer | 82123 0.0814% | $28,135.34 | 1 | 0 | |
| RIGGS RORY B | director | 379200 0.3758% | $129,913.92 | 0 | 7 | |
| Conterno Enrique A | Chief Executive Officer | 374722 0.3713% | $128,379.76 | 2 | 7 | +14.48% |
| Cotroneo Pat | SVP, Finance and CFO | 276677 0.2742% | $94,789.54 | 0 | 51 | |
| Chung Christine | SVP, China Operations | 236327 0.2342% | $80,965.63 | 0 | 29 | |
| Yu K Peony | Chief Medical Officer | 192292 0.1905% | $65,879.24 | 0 | 44 | |
| Eisner Mark | EVP, Chief Medical Officer | 162862 0.1614% | $55,796.52 | 0 | 6 | |
| Routti Jorma | director | 131540 0.1303% | $45,065.60 | 0 | 12 | |
| Kouchakji Elias | SVP, Clinical Dev, Drug Safety | 109199 0.1082% | $37,411.58 | 0 | 1 | |
| VALONE FRANK H MD | Chief Medical Officer | 104684 0.1037% | $35,864.74 | 0 | 9 | |
| Graham Juan | Chief Financial Officer | 71083 0.0704% | $24,353.04 | 0 | 6 | |
| MADERO MIGUEL | director | 55614 0.0551% | $19,053.36 | 0 | 2 | |
| Tamura Toshinari | director | 51700 0.0512% | $17,712.42 | 0 | 4 | |
| Neff Thomas B | Chief Executive Officer | 44238 0.0438% | $15,155.94 | 0 | 201 | |
| KEARNS THOMAS F JR | director | 39764 0.0394% | $13,623.15 | 0 | 15 | |
| EDWARDS JEFFREY L | director | 33977 0.0337% | $11,640.52 | 0 | 1 | |
| Kurkijarvi Kalevi | director | 33100 0.0328% | $11,340.06 | 0 | 41 | |
| Rosenkranz Roberto Pedro | director | 32700 0.0324% | $11,203.02 | 0 | 15 | |
| Ho Maykin | director | 31501 0.0312% | $10,792.24 | 0 | 1 | |
| Blaug Suzanne | director | 29594 0.0293% | $10,138.90 | 0 | 1 | |
| Henderson Jeffrey William | director | 28866 0.0286% | $9,889.49 | 0 | 4 | |
| Cravatt Benjamin | director | 28736 0.0285% | $9,844.95 | 0 | 1 | |
| Brennan Aoife | director | 27947 0.0277% | $9,574.64 | 0 | 1 | |
| Lema Gerald | director | 3500 0.0035% | $1,199.10 | 1 | 0 | +19.61% |
Historical Insider Profitability vs. Competitors
$14,315,062 | 61 | -6.21% | $31.49M | |
$22,186,116 | 57 | -43.73% | $35.93M | |
$53,490,060 | 55 | 19.35% | $31.76M | |
$23,895,365 | 34 | -37.28% | $28.81M | |
$94,084,626 | 29 | -21.08% | $30.58M | |
$167,476,357 | 20 | -1.54% | $38.35M | |
$17,594,514 | 16 | -20.37% | $33.96M | |
$139,007,129 | 16 | 47.16% | $31.71M | |
$819,754 | 12 | -25.19% | $34M | |
$156,381,772 | 11 | 64.80% | $38.29M | |
$3,682,258 | 10 | -34.11% | $40.17M | |
$31,610,161 | 9 | -73.83% | $39.35M | |
$5,574,954 | 8 | -0.97% | $30.58M | |
$232,423 | 8 | 14.22% | $37.7M | |
FibroGen, Inc. (FGEN) | $1,446,995 | 5 | -3.01% | $34.57M |
$147,504 | 5 | -36.70% | $36.65M | |
$1,801,761 | 4 | 54.67% | $37.5M | |
$657,791 | 4 | -52.05% | $38.39M | |
$82,917 | 4 | -11.54% | $31.95M |
FGEN Institutional Investors: Active Positions
| Increased Positions | 25 | +25.51% | 3M | +5.55% |
| Decreased Positions | 38 | -38.78% | 12M | -26.72% |
| New Positions | 11 | New | 746,500 | New |
| Sold Out Positions | 15 | Sold Out | 4M | Sold Out |
| Total Postitions | 85 | -13.27% | 36M | -21.17% |
FGEN Ownership Change vs Market
Institutional Investor Ownership
| Armistice Capital, Llc | $2,142.00 | 6.73% | 6.8M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $1,851.00 | 5.82% | 5.88M | -5,385 | -0.09% | 2024-12-31 |
| Primecap Management Co/Ca/ | $1,454.00 | 4.57% | 4.62M | -5M | -53.42% | 2024-12-31 |
| Acadian Asset Management Llc | $1,230.00 | 3.87% | 3.91M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $749.00 | 2.35% | 2.38M | -14,403 | -0.6% | 2024-12-31 |
| 683 Capital Management, Llc | $674.00 | 2.12% | 2.14M | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $428.00 | 1.35% | 1.36M | +605,572 | +80.41% | 2024-12-31 |
| Marshall Wace, Llp | $399.00 | 1.25% | 1.27M | -179,327 | -12.41% | 2024-12-31 |
| Geode Capital Management, Llc | $333.00 | 1.05% | 1.06M | -25,173 | -2.32% | 2024-12-31 |
| Two Sigma Advisers, Lp | $277.00 | 0.87% | 878,400 | +135,600 | +18.25% | 2024-12-31 |